Key Inclusion Criteria:  The participant has a diagnosis of migraine as defined by International Classification of Headache Disorders Third Edition (ICHD-3) guidelines confirmed at the Screening Visit. The participant has a history of migraine onset at least 12 months prior to the Screening Visit. The participant has a migraine onset of ≤50 years of age. The participant has documented evidence of treatment failure in the past 10 years of at least 2 to 4 (maximum) different migraine preventive medications.  Key Exclusion Criteria:  The participant has been previously dosed with an anti-pituitary adenylate cyclase-activating polypeptide (anti-PACAP) ligand-targeting antibody. The participant has confounding and clinically significant pain syndromes. The participant has a diagnosis of acute or active temporomandibular disorder. The participant has a history or diagnosis of confounding headaches.